Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 plus lenvatinib plus TACE versus TACE in unresectable, non-metastatic hepatocellular carcinoma
CTR20241406Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Aug 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Akeso, Inc.. Started Aug 2024; status: active.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20241406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241406.